Long non‑coding RNA HAND2‑AS1/miR‑106a/PTEN axis re‑sensitizes cisplatin‑resistant ovarian cells to cisplatin treatment

• DOI: 10.3892/mmr.2021.12402
• Publication Date: 2021-09-02T06:55:23Z
• Authors: Lijun Li; Li Li; Lian Hu; Ting Li; Dan Xie; Xiaoliu Liu
• Keywords: Viability assay

Cisplatin (DDP) resistance in patients suffering from ovarian cancer is a considerable hurdle to successful treatment. The present study aimed identify possible long non‑coding RNA (lncRNA)‑microRNA (miRNA)‑mRNA axis participating DDP‑resistance based on the critical roles of RNAs, including lncRNAs and miRNAs, carcinogenesis. According online data experimental results, lncRNA HAND2‑AS1 expression was significantly downregulated within carcinoma, especially recurrent DDP‑resistant carcinoma. also shown be markedly inhibited SKOV3/DDP cells with DDP. In cells, overexpression cell viability promoted apoptosis upon DDP treatment through Bcl‑2/caspase‑3 apoptotic signaling. It hypothesized that PTEN mRNA while rescued proteins blocked PI3K/AKT signaling activation. Moreover, miR‑106a found bind directly 3' UTR HAND2‑AS1. Upon treatment, viability. pathway protein levels upregulated activity. Furthermore, partially reversed effect proliferation conclusion, HAND2‑AS1/miR‑106a/PTEN re‑sensitizes has been established.